Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$16.98 USD
+0.17 (1.01%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $16.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.98 USD
+0.17 (1.01%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $16.98 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Zacks News
Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report
by Zacks Equity Research
Here are the key takeaways from Eli Lilly's (LLY) fourth-quarter earnings conference call.
Earnings & Data Deluge
by Zacks Equity Research
Earnings & Data Deluge
Markets Keeping Optimistic... For Now; Plus HLT, TEVA, DISH
by Mark Vickery
Pre-market futures are again trading up today, as expectations continue to be favorable for two things that have yet to be officially resolved.
Teva (TEVA) Misses on Q4 Earnings, Beats Sales, Shares Down
by Zacks Equity Research
Teva's (TEVA) fourth-quarter earnings misses estimates but sales beat expectations. Teva???s sales and earnings guidance for 2019 is weaker than expected.
Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $18.22, marking a -0.71% move from the previous day.
Teva (TEVA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.
Lilly (LLY) Lags Q4 Earnings, Lowers 2019 View, Stock Down
by Zacks Equity Research
Eli Lilly (LLY) misses estimates for earnings but beats the same for sales. The company lowers its previously issued guidance for earnings and sales. Stock drops in pre-market trading.
Why the Earnings Surprise Streak Could Continue for Teva Pharmaceutical Industries Ltd. (TEVA)
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy
by Zacks Equity Research
Teva (TEVA) receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP), advocating a marketing approval for its new migraine medicine, Ajovy.
Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $19.70, moving -0.76% from the previous trading session.
J&J's Erleada Meets Both Primary Endpoints in Late-Stage Study
by Zacks Equity Research
Johnson & Johnson's (JNJ) Erleada improves survival in metastatic castration-sensitive prostate cancer study.
Lilly/Pfizer's Osteoarthritis Pain Drug Succeeds in 2nd Study
by Zacks Equity Research
Eli Lilly (LLY) and Pfizer announce that their investigational pain candidate, tanezumab, achieves significant reduction in pain in osteoarthritis patients in second late-stage study.
Amgen (AMGN) Q4 Earnings Beat Estimates, 2019 Guidance Tepid
by Zacks Equity Research
Amgen (AMGN) beats estimates for both earnings and sales in Q4. Its forecast for 2019 disappoints investors Stock dips 2.4% in after-hours trading.
AbbVie's Imbruvica Combo Gets FDA Nod in First-Line Setting
by Zacks Equity Research
AbbVie's (ABBV) key cancer drug, Imbruvica, in combination with Gazyva, gets FDA approval for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in first-line setting.
Allergan Hikes Quarterly Dividend by 2.8% Ahead of Q4 Results
by Zacks Equity Research
Allergan (AGN) approves a cash dividend of 74 cents for 2019, a 2.8% raise from the previous payout of 72 cents.
Merck's Partner Gets FDA Nod for Herceptin Biosimilar
by Zacks Equity Research
Merck's (MRK) partner, Samsung Bioepis Co. gets FDA approval for Ontruzant, a Herceptin Biosimilar.
Teva Pharmaceutical Industries Ltd. (TEVA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $18.76, moving +0.59% from the previous trading session.
6 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2019
by Zacks Equity Research
Here are five reasons which investors may consider while investing in Lilly's (LLY) stock.
Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $18.45 in the latest trading session, marking a +1.54% move from the prior day.
INSYS Therapeutics Rises on Dose-Ranging Allergy Study Data
by Zacks Equity Research
INSYS Therapeutics' (INSY) epinephrine nasal spray demonstrates pharmacokinetic profile similar to two reference products EpiPen and Adrenalin in treating patients with anaphylaxis, a life-threatening allergic reaction.
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Teva Pharmaceutical Industries, Visa, American Express, Liberty Latin America and Sirius XM
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Teva Pharmaceutical Industries, Visa, American Express, Liberty Latin America and Sirius XM
5 Must-Watch Warren Buffett Stocks for 2019
by Tirthankar Chakraborty
We have selected five of Oracle of Omaha's favored companies that are likely to make the most of this year. Most of these companies belong to sectors such as health care, financials and communication services.
Regeneron, Sanofi Restructure Immuno-Oncology Collaboration
by Zacks Equity Research
Regeneron (REGN) amends its existing agreement with Sanofi and selects two clinical-stage bispecific antibodies for the ongoing collaboration.
VIVUS (VVUS) Banks on New Drug Pancreaze, Qsymia Lacks Luster
by Zacks Equity Research
Although VIVUS (VVUS) is struggling with its legacy products, promotional initiatives and addition of cash-flow positive assets bode well for the company.
Teva (TEVA) Ends Dispute with Amgen Over Generic Sensipar
by Zacks Equity Research
Teva (TEVA) ends an ongoing patent dispute with Amgen over generic Sensipar by making an undisclosed payment.